Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact of endocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended effect of aromatase inhibitors.
INTRODUCTION
Cholesterol-lowering drugs are frequently prescribed for prevention of cardiovascular disease, with statins being the most widely used drug class. 1 Recent reports suggest a possible role of statins in preventing breast cancer recurrence. [2] [3] [4] [5] In addition to the primary hepatic functions of statins, extrahepatic functions of statins may affect the mevalonate pathway in cancer cells by targeting the rate-limiting enzyme HMG-CoA reductase. [6] [7] [8] HMG-CoA reductase is differentially expressed in breast cancer and has been identified as a prognostic marker, 9 ,10 which may indicate a potential differential response to statins among patients with breast cancer. 11 If statins inhibit the mevalonate pathway in breast tumors, lowered intracellular cholesterol may lead to reduced intratumoral autocrine hormone production, because cholesterol is fundamental for steroid hormone synthesis. 12 The possible anticancer effects of cholesterol-lowering medication (CLM), including statins, may indirectly affect tumors through the systemic lowering of cholesterol levels and accompanying reduced levels of the cholesterol metabolite 27-hydroxycholesterol (27HC). 13, 14 27HC acts as an estrogen receptor (ER) ligand and has been shown to regulate ER-dependent tumor growth. 12, 14 The systemic lowering of cholesterol levels may also deprive tumor cells of their increased demand for cholesterol uptake. [15] [16] [17] Thus, assessment of both statins and other CLMs is necessary when evaluating the potential impact of systemic cholesterol reduction on breast cancer outcomes.
Postmenopausal patients with hormone receptor-positive breast cancer are primarily treated with tamoxifen and/or aromatase inhibitors (AIs). 18 Hypercholesterolemia during treatment with AIs may reduce the intended effect of AIs, given the evidence for ER potentiation by 27HC.
14 AI-treated patients with breast cancer with incident hypercholesterolemia may therefore benefit from concomitant CLM treatment. Conversely, tamoxifen reduces cholesterol levels, 19, 20 and concomitant CLM may have less clinical impact.
Given the data from preclinical studies on mechanisms of action of CLM against breast cancer cells, as well as the clinical data from patient cohorts, we hypothesized that CLM in combination with endocrine therapy may improve breast cancer outcomes. We evaluated this hypothesis in the Breast International Group 1-98 (BIG 1-98) trial after 8 years median follow-up after initiation of adjuvant endocrine therapy.
PATIENTS AND METHODS

Patients
The BIG 1-98 study enrolled 8,010 postmenopausal women diagnosed with early-stage (ie, operable and planned for adjuvant endocrine treatment) ER-positive invasive breast cancer from 1998 to 2003. In this randomized, phase III, double-blind trial, patients were randomly assigned within two randomization options: two arm (1998 to 2000) or four arm (1999 to 2003). The two-arm option compared tamoxifen (20 mg per day) with the AI letrozole (2.5 mg per day) each for 5 years, whereas the fourarm option also included the two sequential arms of tamoxifen for 2 years followed by letrozole for 3 years or letrozole for 2 years followed by tamoxifen for 3 years. Detailed information regarding study design, eligibility, and conduct was previously reported. [21] [22] [23] The cohort used in our analysis was restricted to patients who received at least one dose of study therapy (n = 7,963) and was then further refined to correspond to our individual analytic aims (Fig 1) . All BIG 1-98 trial participants provided written informed consent. Ethics committees and relevant health authorities approved the protocol.
Analytic Variables
Trial baseline case report forms collected, under relevant history and concurrent medical conditions, hypercholesterolemia (1.53 upper limit of normal) with date of most recent diagnosis. Baseline forms also collected medication for hypercholesterolemia (agent and dates). At each 6-month visit during treatment, cholesterol levels and CLM use (including dates) were assessed.
24 CLM included all cholesterol-lowering medications (both statins and nonstatins). The protocol included no recommendations for CLM use, and decisions regarding CLM prescription were made at the discretion of the treating physician. Study end points included disease-freesurvival (DFS), defined as time from random assignment until the earliest occurrence of invasive locoregional recurrence, distant metastasis, invasive contralateral breast cancer, second non-breast primary malignancy, or death from any cause; breast cancer-free interval (BCFI), defined as time from random assignment until the earliest occurrence of invasive breast cancer event (locoregional recurrence, distant metastasis, or invasive contralateral breast cancer); and distant recurrence-free interval (DRFI), defined as time from random assignment until the occurrence of distant breast cancer metastasis. In the absence of an event, follow-up was censored at date of last visit (for BCFI and DRFI, this included censoring at death without cancer or distant metastasis event). Follow-up of patients assigned to tamoxifen monotherapy who selectively crossed to letrozole therapy after trial results were reported in 2005 was censored at the time of the crossover. 23 
Statistical Analyses
Four analyses in corresponding analytic cohorts (Fig 1) were conducted to determine cholesterol levels over time according to assigned endocrine therapy, the association of prior CLM exposure at start of endocrine therapy on breast cancer outcomes, time to initiation of CLM according to assigned endocrine therapy, and the effects of CLMs initiated during endocrine therapy on breast cancer outcomes.
Cholesterol levels over time according to randomized endocrine therapy. These investigations included patients who received at least one dose of study therapy and had no history of CLM at the start of endocrine therapy (n = 7,326; Fig 1) . Longitudinal cholesterol levels were summarized with box plots.
CLM use at start of endocrine therapy and breast cancer outcomes. This analysis included all patients who received at least one dose of study therapy (n = 7,963; Fig 1) . Patients were classified into two CLM exposure groups: (1) no prior exposure to CLM and (2) current or past use of CLM. We used Kaplan-Meier estimates of DFS, BCFI, and DRFI according to CLM exposure (yes/no) at the start of endocrine therapy and multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CIs. Models included age at random assignment (continuous), body mass index, tumor size and grade, nodal status, presence of peritumoral vascular invasion, type of breast surgery, receipt of radiotherapy, history of diabetes, history of cardiac events, and location of enrolling institution, in addition to CLM exposure. All Cox models were stratified by assigned endocrine therapy, randomization option (two arm or four arm), and prior chemotherapy (yes/no).
Time to initiation of CLM according to assigned endocrine therapy. Time to initiation of CLM according to assigned endocrine therapy included patients who were not exposed to CLM at the start of endocrine therapy (n = 7,326; Fig 1) . We estimated cumulative incidence functions in the presence of competing risks 25 of death not preceded by the initiation of CLM or cessation of study therapy for any reason.
CLM use during endocrine therapy and breast cancer outcomes. This analysis included patients who were not exposed to CLM at the start of endocrine therapy and who had serum cholesterol measurements at the time of or within 30 days after study enrollment (n = 5,944; Fig 1) . Followup for each patient was divided into intervals corresponding to the 6-month study visits. If a patient began CLM during a 6-month interval but before the end of study therapy, the patient was reclassified for CLM use during that time interval. The analysis assumes that once a patient initiated CLM, she continued throughout the remaining follow-up.
Marginal structural Cox proportional hazards models were used to address potential bias in associations between CLM and breast cancer outcomes as a result of cholesterol level, assigned endocrine therapy, individual patient risk factors, changes in practice over time, and location of enrolling institution. 26 This modeling technique required two steps for each end point. The first step created stabilized time-varying exposure probability weights for each patient, incorporating her unique medical, demographic, and treatment history. Estimation of the time-varying weights was based on multivariable logistic regression of CLM use during a given time interval on medical, demographic, and treatment factors. Countries were grouped geographically and roughly according to their different approaches to prescribing CLM. The numerator probability of each weight was modeled by using baseline factors and assigned therapy. The denominator probability of each weight was modeled by using the same baseline factors and assigned therapy plus time-varying factors, including cholesterol level, incident cardiac event, or incident thromboembolic event during study therapy. Models for the weights were not necessarily parsimonious and included relevant prognostic factors regardless of statistical significance. If a cholesterol measurement was missing in a given time interval for a patient, it was carried forward from the previous nonmissing time interval.
In the second step, associations between CLM use and DFS, BCFI, or DRFI were estimated with Cox models that used the time-varying weights. The weighted Cox models were stratified by chemotherapy use and randomization option. Univariate models had only the time-varying use of CLM as the predictor. Because the models for the time-varying weights may not have included standard prognostic factors, the multivariable models included the time-varying use of CLM, breast cancer disease, treatment characteristics, and assigned endocrine therapy as covariates. As part of this modeling, it was necessary for us to assume that the prescription of CLM could be completely described by each patient's potential comorbidities (ie, hypercholesterolemia or a cardiac event). We also assumed that once a patient began CLM, she continued throughout follow-up. Associations are reported as HRs with 95% robust Wald CIs. All analyses were performed by using SAS version 9.4 (SAS Institute, Cary, NC). All statistical tests were two-sided with a 5% type I error and no corrections for multiple comparisons.
RESULTS
Cholesterol Levels Over Time According to Randomized Treatment
Serum cholesterol levels decreased during tamoxifen treatment and returned to pre-tamoxifen levels after tamoxifen treatment ended, whether given alone, prior to, or after letrozole. Serum cholesterol levels remained unchanged from baseline levels during letrozole, whether given alone, prior to, or after tamoxifen (Data Supplement).
Use of CLM at Start of Endocrine Therapy and Breast Cancer Outcomes
Among the 7,963 patients who received at least one dose of study therapy, 637 (8%) reported prior exposure to CLM at the start of endocrine therapy. Compared with patients who did not use CLM, patients with prior CLM exposure were older, less likely to be current smokers, and more likely to have diabetes mellitus, a cardiac medical history, smaller tumors, and fewer positive lymph nodes at diagnosis (Table 1) . Patients who were exposed to CLM at start of endocrine therapy (n = 637) had an 18% reduction in DFS hazard compared with those not exposed to CLM (n = 7,326; DFS HR adj , 0.82; 95% CI, 0.68 to 0.99), a 17% lower hazard of a breast cancer recurrence (BCFI HR adj , 0.83; 95% CI, 0.65 to 1.06), and a 19% lower hazard of distant recurrence (DRFI HR adj , 0.81; 95% CI, 0.61 to 1.09; Table 2 and Data Supplement).
Time to Initiation of CLM According to Assigned Endocrine Therapy
Among the 7,326 patients not exposed to CLM at the start of endocrine therapy, 789 (10.8%) initiated CLM at some point while receiving study therapy. The incidence of CLM initiation varied across assigned endocrine therapy groups, with letrozole monotherapy having the highest incidence, followed by the two sequential letrozole-containing groups. By 5 years of treatment, approximately 5% of patients receiving tamoxifen had initiated CLM. In contrast, patients assigned to letrozole-containing groups had a much higher incidence of initiating CLM, and by 5 years, the cumulative incidences of CLM in the sequential groups were similar to those in the letrozole monotherapy group (18% letrozole, 15% tamoxifen-letrozole, 14% letrozole-tamoxifen [fourarm]; Fig 2) .
CLM Use During Endocrine Therapy and Breast Cancer Outcomes
Characteristics of patients, disease, and treatment, according to whether patients initiated CLM during endocrine therapy, revealed imbalances between CLM groups for treatment assignment, year of Table 1 enrollment, tumor grade, body mass index, history of diabetes mellitus, location of enrollment, and smoking history (Table 3) .
According to marginal structural Cox models, initiation of CLM during any endocrine therapy appeared to be associated with improved DFS (HR adj , 0.79; 95% CI, 0.66 to 0.95; P = .01), BCFI (HR adj , 0.76; 95% CI, 0.60 to 0.97; P = .02), and DRFI (HR adj , 0.74; 95% CI, 0.56 to 0.97; P = .03; Table 4 ). There was no statistically significant interaction between CLM initiation and assigned endocrine treatment.
In analyses of the two monotherapy arms, initiation of CLM showed no benefit on clinical outcome in the tamoxifen arm DFS (HR adj , 0.99; 95% CI, 0.56 to 1.74; P = .97), BCFI (HR adj , 0.85; 95% CI, 0.42 to 1.74; P = .44), and DRFI (HR adj , 0.57; 95% CI, 0.24 to 1.35; P = .20), and a nonsignificant trend toward a benefit among patients in the letrozole arm DFS (HR adj , 0.66; 95% CI, 0.40 to 1.08; P = .10), BCFI (HR adj , 0.77; 95% CI, 0.40 to 1.48; P = .44), and DRFI (HR adj , 0.70; 95% CI, 0.31 to 1.59; P = 0.40; Data Supplement).
DISCUSSION
In this report from the BIG 1-98 study, patients with breast cancer who received adjuvant endocrine therapy experienced decreased serum cholesterol levels during tamoxifen monotherapy, whereas in patients assigned to letrozole, serum cholesterol remained at the pre-endocrine therapy level. Patients with breast cancer who used CLM at study baseline had more beneficial tumor characteristics and improved outcomes compared with nonusers. The prognostic impact of CLM initiation during endocrine therapy showed beneficial effects of initiating CLM, although the benefit may be restricted to patients who received letrozole.
To the best of our knowledge, this study is the first to support the beneficial effect of CLM on breast cancer outcome that is based on a large, international, prospectively conducted, randomized clinical trial of modern adjuvant endocrine therapy 31 showing that prior use of lipophilic statins was associated with a reduction in late-stage breast cancer diagnosis. The inverse associations between CLM use and breast cancer stage may thus account for some of the breast cancer survival benefits demonstrated in this and in previous studies [2] [3] [4] [27] [28] [29] [30] ; however, analyses were adjusted for disease characteristics, including stage. Furthermore, healthy user bias might affect the associations if prior CLM users were more frequently undergoing breast cancer surveillance, which increases the likelihood of a breast cancer diagnosis at an earlier stage. Information on mammography screening among BIG 1-98 patients unfortunately was not available; however, adjusted analyses accounted for disease stage. Assuming that CLM was more often prescribed to healthier patients with breast cancer, a healthy user bias effect may also have influenced the longitudinal analyses of postdiagnostic initiation of CLM among patients with breast cancer in this double-blind randomized clinical trial population. Adjusting for competing factors such as history of diabetes, cardiac events, or smoking, attempted to control for the likelihood of CLM being prescribed more often to healthier patients.
Another challenge in the analyses of CLM and its association with breast cancer is the role of cholesterol levels, which have been shown to be associated with both risk of breast cancer 32,33 and prognosis. 34 Hypercholesterolemia is one the main indications for CLM, and confounding by indication could influence the results. There are several sources of bias in the data as a result of the interrelationships between the use of CLM and cholesterol level, treatment assignment (which was blinded), risk factors, changes in practice over time, and location of enrolling institution. Some of these factors may cause time-dependent confounding of the associations between CLM use and breast cancer outcomes, which could not be addressed adequately by using extended Cox models with CLM as a time-dependent covariate. To account for confounding, we applied marginal structural Cox proportional hazards modeling. 26 Although we continued to observe protective associations between CLM use and breast cancer outcomes based on these models, we cannot rule out the possibility of some residual bias.
Although this study is based on routinely collected clinical trial data from a randomized trial, it is primarily observational. It should be noted that BIG 1-98 was not designed to specifically address the questions raised in this study. Serum cholesterol and CLM data were collected as part of the overall safety evaluation on the basis of information available in 1998 when the trial started. Information on medical reasons for why CLM was prescribed, metabolic factors, and more precise cholesterol and CLM details were not collected but would be important for future studies specifically designed to study CLM and breast cancer.
Several registry-based studies have reported protective associations between CLM (eg, statins) and outcomes among women with ER-positive breast cancer. 2, 31 Of note, a large, prospective Danish study that evaluated the risk of recurrence in relation to use of statins did not show any modification of associations by the ER status of the primary tumor, 2 which argues against an enhanced action against ER-negative breast cancer as indicated in functional studies. 8, 35 In addition, previous presurgical studies have not Years After Randomization Given the estrogenic effects of 27HC, 14,38 hypercholesterolemia during letrozole treatment 39 may have an impact on the effectiveness of endocrine treatment, possibly threatening the intended clinical effects. Considering the diverse impact of specific endocrine treatment on cholesterol levels, we hypothesized that CLM initiation may be especially relevant for patients receiving letrozole. We found that the patients treated with letrozole monotherapy demonstrated effects that were comparable in magnitude to the overall effect of CLM initiation but were nonsignificant. Conversely, women treated with tamoxifen monotherapy did not appear to benefit from CLM initiation. We recognize, however, that low numbers of patients in these analyses limit the interpretation of these results.
Future studies assessing CLM use among patients with breast cancer who are receiving endocrine treatment may enrich our understanding of factors that influence the effectiveness of endocrine therapy and the role of CLM in treating breast cancer. In the BIG 1-98 trial, initiation of CLM while receiving adjuvant endocrine therapy improved clinical outcome for patients with ERpositive breast cancer. The evidence from our observational study warrants consideration of a large prospective randomized clinical trial to confirm the value of CLM concomitant with endocrine treatment of breast cancer. Further elucidation of the effect upon outcome of the clinical interaction between CLM and endocrine agents-both widely used by patients with breast cancer-will provide exclusive insight to future trial designs. Abbreviations: BCFI, breast-cancer-free interval; CLM, cholesterol-lowering medication; DFS, disease-free survival, DRFI, distant recurrence-free interval; HR, hazard ratio. *Includes CLM as time-varying covariate.
†Includes CLM and cholesterol as time-varying covariates, with treatment assignment, nodal status, tumor size and grade, peritumoral vascular invasion, and local therapy as covariates in the model. The analysis was stratified by randomization option and prior chemotherapy use.
